Video

Dr. Lenz on Updated Results of the CheckMate-142 Trial in mCRC

Heinz-Josef Lenz, MD, FACP, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer.

Heinz-Josef Lenz, MD, FACP, professor of medicine, J. Terrance Lanni Chair in Gastrointestinal Cancer Research, and co-director, University of Southern California (USC) Center for Molecular Pathway and Drug Discovery, at the USC Norris Comprehensive Cancer Center, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer (mCRC).

The trial examined frontline nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) in treatment-naïve patients with microsatellite instability-high/mismatch repair deficient mCRC.

At a median follow-up of 25.4 months, the objective response rate was 58%. Moreover, progression-free survival (PFS) was not yet reached with the combination.

These data suggest that the combination can provide patients with durable benefit,says Lenz.

Related Videos
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Andrew Davis, MD
Noa Biran, MD